【24h】

Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling

机译:通过药效团建模鉴定HDACs抑制剂必不可少的配体特征

获取原文

摘要

Histone deacetylases (HDACs) enzyme plays a significant role in transcriptional regulation by modifying the core histones of the nucleosome. It has emerged as an important therapeutic target for the treatment of cancer and other diseases. Inhibitors of HDACs become a new class of anticancer agents and have provoked much interest amongst pharmacologists and cancer researchers. To facilitate the discovery of specific HDACs inhibitors, a 3D chemical-feature-based QSAR pharmacophore model was developed and was well consistent with the structure-functional requirements for the binding of the HDAC inhibitors. Using this model, the interactions between the benzamide MS-275 and HDAC were explored. The result showed that the type and spatial location of chemical features encoded in the pharmacophore are in full agreement with the enzyme inhibitor interaction pattern identified from molecular docking.
机译:组蛋白脱乙酰基酶(HDACs)酶通过修饰核小体的核心组蛋白在转录调控中起重要作用。它已成为治疗癌症和其他疾病的重要治疗靶标。 HDAC的抑制剂已成为一类新型的抗癌药,引起了药理学家和癌症研究人员的极大兴趣。为了促进发现特定的HDAC抑制剂,开发了一种基于3D化学特征的QSAR药效团模型,该模型与HDAC抑制剂结合的结构功能要求非常一致。使用该模型,研究了苯甲酰胺MS-275和HDAC之间的相互作用。结果表明,药效基团中编码的化学特征的类型和空间位置与从分子对接确定的酶抑制剂相互作用模式完全一致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号